U.S. Markets closed
  • S&P Futures

    3,409.50
    -23.00 (-0.67%)
     
  • Dow Futures

    27,954.00
    -180.00 (-0.64%)
     
  • Nasdaq Futures

    11,617.75
    -73.50 (-0.63%)
     
  • Russell 2000 Futures

    1,593.10
    -10.00 (-0.62%)
     
  • Crude Oil

    39.77
    -0.26 (-0.65%)
     
  • Gold

    1,916.50
    -13.00 (-0.67%)
     
  • Silver

    24.86
    -0.38 (-1.51%)
     
  • EUR/USD

    1.1843
    -0.0024 (-0.2013%)
     
  • 10-Yr Bond

    0.8160
    +0.0190 (+2.38%)
     
  • Vix

    28.65
    -0.70 (-2.39%)
     
  • GBP/USD

    1.3129
    -0.0014 (-0.1090%)
     
  • USD/JPY

    104.6940
    +0.1340 (+0.1282%)
     
  • BTC-USD

    12,805.46
    +1,748.45 (+15.81%)
     
  • CMC Crypto 200

    256.57
    +11.68 (+4.77%)
     
  • FTSE 100

    5,776.50
    -112.72 (-1.91%)
     
  • Nikkei 225

    23,485.95
    -81.05 (-0.34%)
     

Here's Why We're Watching Armata Pharmaceuticals's (NYSEMKT:ARMP) Cash Burn Situation

Simply Wall St
·4 mins read

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?

So, the natural question for Armata Pharmaceuticals (NYSEMKT:ARMP) shareholders is whether they should be concerned by its rate of cash burn. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. Let's start with an examination of the business' cash, relative to its cash burn.

See our latest analysis for Armata Pharmaceuticals

How Long Is Armata Pharmaceuticals's Cash Runway?

A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. In March 2020, Armata Pharmaceuticals had US$24m in cash, and was debt-free. In the last year, its cash burn was US$18m. Therefore, from March 2020 it had roughly 17 months of cash runway. That's not too bad, but it's fair to say the end of the cash runway is in sight, unless cash burn reduces drastically. The image below shows how its cash balance has been changing over the last few years.

AMEX:ARMP Debt to Equity History June 30th 2020
AMEX:ARMP Debt to Equity History June 30th 2020

How Is Armata Pharmaceuticals's Cash Burn Changing Over Time?

Because Armata Pharmaceuticals isn't currently generating revenue, we consider it an early-stage business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. Over the last year its cash burn actually increased by a very significant 64%. Oftentimes, increased cash burn simply means a company is accelerating its business development, but one should always be mindful that this causes the cash runway to shrink. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

How Hard Would It Be For Armata Pharmaceuticals To Raise More Cash For Growth?

Given its cash burn trajectory, Armata Pharmaceuticals shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Commonly, a business will sell new shares in itself to raise cash and drive growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn.

Armata Pharmaceuticals has a market capitalisation of US$76m and burnt through US$18m last year, which is 23% of the company's market value. That's not insignificant, and if the company had to sell enough shares to fund another year's growth at the current share price, you'd likely witness fairly costly dilution.

So, Should We Worry About Armata Pharmaceuticals's Cash Burn?

On this analysis of Armata Pharmaceuticals's cash burn, we think its cash runway was reassuring, while its increasing cash burn has us a bit worried. We don't think its cash burn is particularly problematic, but after considering the range of factors in this article, we do think shareholders should be monitoring how it changes over time. On another note, Armata Pharmaceuticals has 6 warning signs (and 3 which shouldn't be ignored) we think you should know about.

Of course Armata Pharmaceuticals may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.